OPTIPHARM.CO.,LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6,680 KRW | +0.15% |
|
+3.89% | -4.98% |
| 2023 | Optipharm.CO.,LTD Reports Earnings Results for the First Quarter Ended March 31, 2023 | CI |
| 2022 | Optipharm.CO.,LTD(KOSDAQ:A153710) dropped from S&P Global BMI Index | CI |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 130,657 | 129,975 | 220,012 | 137,287 | 102,836 | 103,130 |
| Enterprise Value (EV) 1 | 108,781 | 108,020 | 202,324 | 121,161 | 93,939 | 97,525 |
| P/E ratio | -188 x | -198 x | -93.1 x | -44.5 x | -50.2 x | -42.3 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 9.36 x | 9.52 x | 16.9 x | 9.63 x | 6.42 x | 5.94 x |
| EV / Revenue | 7.79 x | 7.91 x | 15.5 x | 8.5 x | 5.87 x | 5.61 x |
| EV / EBITDA | 16,652 x | -323 x | -81.9 x | -35.3 x | -41.6 x | -81.4 x |
| EV / FCF | 139 x | -171 x | -71.2 x | -55.8 x | -13 x | -48.6 x |
| FCF Yield | 0.72% | -0.58% | -1.41% | -1.79% | -7.7% | -2.06% |
| Price to Book | 3.69 x | 3.65 x | 6.51 x | 4.44 x | 3.54 x | 4.11 x |
| Nbr of stocks (in thousands) | 14,217 | 14,378 | 14,474 | 14,589 | 14,670 | 14,670 |
| Reference price 2 | 9,190 | 9,040 | 15,200 | 9,410 | 7,010 | 7,030 |
| Announcement Date | 3/1/19 | 2/29/20 | 3/1/21 | 3/1/22 | 3/1/23 | 2/29/24 |
1KRW in Million2KRW
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 13,958 | 13,653 | 13,046 | 14,258 | 16,008 | 17,373 |
| EBITDA 1 | 6.533 | -334.3 | -2,469 | -3,429 | -2,257 | -1,198 |
| EBIT 1 | -696.4 | -1,191 | -3,454 | -4,505 | -3,377 | -2,631 |
| Operating Margin | -4.99% | -8.72% | -26.47% | -31.59% | -21.1% | -15.14% |
| Earnings before Tax (EBT) 1 | -604.5 | -655.3 | -2,352 | -3,080 | -2,045 | -2,437 |
| Net income 1 | -604.5 | -655.3 | -2,352 | -3,080 | -2,045 | -2,437 |
| Net margin | -4.33% | -4.8% | -18.03% | -21.6% | -12.77% | -14.03% |
| EPS 2 | -48.82 | -45.72 | -163.3 | -211.6 | -139.6 | -166.0 |
| Free Cash Flow 1 | 783.3 | -630.5 | -2,843 | -2,171 | -7,229 | -2,006 |
| FCF margin | 5.61% | -4.62% | -21.79% | -15.22% | -45.16% | -11.55% |
| FCF Conversion (EBITDA) | 11,990.77% | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 3/1/19 | 2/29/20 | 3/1/21 | 3/1/22 | 3/1/23 | 2/29/24 |
1KRW in Million2KRW
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 21,875 | 21,954 | 17,688 | 16,126 | 8,897 | 5,605 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | 783 | -631 | -2,843 | -2,171 | -7,229 | -2,006 |
| ROE (net income / shareholders' equity) | -2.51% | -1.84% | -6.78% | -9.51% | -6.82% | -9% |
| ROA (Net income/ Total Assets) | -1.39% | -1.76% | -5.2% | -6.83% | -5.13% | -4.09% |
| Assets 1 | 43,389 | 37,133 | 45,249 | 45,116 | 39,887 | 59,615 |
| Book Value Per Share 2 | 2,493 | 2,477 | 2,334 | 2,122 | 1,978 | 1,710 |
| Cash Flow per Share 2 | 1,849 | 1,404 | 1,086 | 561.0 | 380.0 | 153.0 |
| Capex 1 | 203 | 626 | 891 | 725 | 4,572 | 1,672 |
| Capex / Sales | 1.45% | 4.59% | 6.83% | 5.09% | 28.56% | 9.62% |
| Announcement Date | 3/1/19 | 2/29/20 | 3/1/21 | 3/1/22 | 3/1/23 | 2/29/24 |
1KRW in Million2KRW
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -4.98% | 71.13M | |
| -18.97% | 72.97B | |
| -11.11% | 6.69B | |
| -3.48% | 3.13B | |
| +2.36% | 1.44B | |
| -15.13% | 1.34B | |
| -7.91% | 1.25B | |
| -25.63% | 1.24B | |
| -10.84% | 1.15B | |
| 0.00% | 1.01B |
- Stock Market
- Equities
- A153710 Stock
- Financials Optipharm.CO.,LTD
